POLYBRAINT-Versatile Polypeptide-based Intranasal Drug Delivery Platform(s) to Tackle CNS Disorders.
FUNDING AGENCY: ERC-2022-PoC-101069391.
LENGTH: 01/04/2022 to 30/11/2023
PRINCIPAL INVESTIGATOR: Dr. María J. Vicent.
POLYBRAINT will explore the potentiality to drive innovation of an intranasal drug delivery platform to deliver biologics to the brain, thereby advancing the development of nanotherapies for central nervous system disorders. Our nanocarriers can reach and diffuse through the brain even to specific areas of interest.
In this ERC PoC we will (1) confirm that the biologic cargo is transported, released in a controlled manner and pharmacologically functional; (2) performed benchmark studies; (3) establish IP strategy and acquire IP protection, and (4) establish the viability and direction towards a future commercialisation stage.